Trial Profile
Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Belantamab mafodotin (Primary) ; Cobimetinib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Enasidenib (Primary) ; Erdafitinib (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary) ; Selinexor (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MyDRUG
- 12 Dec 2023 Results (n=17) reporting safety and efficacy data of sub-protocol Y3 arm of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Initial observations of dynamic transcriptional changes in specific immune and myeloma cell compartments that are associated with targeting the MAPK pathway in the MyDrug C1 sub protocol, results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results(n=38 from Y1 daratumumab arm) assessing safety and efficacy of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma presented at the 64th American Society of Hematology Annual Meeting and Exposition